IBTROZI is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). (1)
Ibtrozi: Uses, Dosage, Side Effects & Warnings - Drugs.com
Jun 12, 2025 · Ibtrozi is used to treat non-small cell lung cancer (NSCLC) in adults that has spread within the chest or to other parts of the body and is caused by an abnormal ROS1 …
Ibtrozi (taletrectinib): Uses, Side Effects, Interactions ... - WebMD
Jun 29, 2025 · Find patient medical information for Ibtrozi (taletrectinib) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings
ROS1+ NSCLC Therapy | IBTROZI™ (taletrectinib)
IBTROZI™ is a targeted treatment for adult patients with locally advanced or metastatic ROS1+ NSCLC. See Full Prescribing & Safety Info.
Taletrectinib (Ibtrozi) 2025 Updates: Uses in Cancer, Side effects ...
Jul 10, 2025 · Taletrectinib (Ibtrozi) is target therapy for ROS1 mutated NSCLC. Learn about its uses, side effects, dosage, what to expect during treatment.
With lung cancer FDA nod, it's David versus Goliath
Jun 11, 2025 · Nuvation Bio has won FDA approval for Ibtrozi, or taletrectinib, to challenge existing meds from Pfizer, BMS and Roche in ROS1-positive lung cancer.
FDA Approves Taletrectinib in ROS1+ NSCLC | CancerNetwork
Jun 11, 2025 · The FDA has approved taletrectinib (Ibtrozi) for patients with locally advanced or metastatic ROS1 -positive non–small cell lung cancer (NSCLC), according to a press release …
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI …
Jun 11, 2025 · NEW YORK-- (BUSINESS WIRE)-- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, …
FDA Approves Talectrectinib (Ibtrozi) for ROS1-Positive Lung Cancer
On June 11, 2025, the U.S. Food and Drug Administration (FDA) approved taletrectinib (Ibtrozi), a new targeted therapy for adults with locally advanced or metastatic ROS1-positive non-small …
FDA approves taletrectinib for ROS1-positive non-small cell lung …
On June 11, 2025, the Food and Drug Administration approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small ...